{"id":9890,"date":"2025-05-26T20:11:50","date_gmt":"2025-05-26T20:11:50","guid":{"rendered":"https:\/?page_id=9890"},"modified":"2025-06-06T17:07:42","modified_gmt":"2025-06-06T17:07:42","slug":"immuno-oncology-2","status":"publish","type":"page","link":"https:\/\/eutranslationalmedicine.org\/aii\/immuno-oncology-2\/","title":{"rendered":"Immuno-Oncology"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t\t\t\t
\n\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tImmuno-Oncology\t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/h1>\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Immuno-oncology is transforming cancer treatment by harnessing the power of the immune system to identify and eliminate tumors. Leading pharmaceutical and biotech companies are advancing a wide range of innovative approaches across the immuno-oncology landscape. Below are the key areas of focus shaping the future of cancer immunotherapy:<\/p>

Key Areas:<\/strong><\/h5>

  • Immune Checkpoint Inhibitors<\/strong>
    Targeting PD-1, PD-L1, CTLA-4, TIGIT, and LAG-3 to overcome immune suppression and reinvigorate T-cell responses.<\/p><\/li>

  • T-Cell Engaging Bispecific Antibodies<\/strong>
    Dual-targeting antibodies that redirect T cells to cancer cells, enabling precise and potent tumor cell killing.<\/p><\/li>

  • CAR-T Cell Therapy<\/strong>
    Genetically engineered T cells that recognize specific cancer antigens, primarily for blood cancers, with ongoing expansion into solid tumors.<\/p><\/li>

  • TCR-T Cell Therapy<\/strong>
    T cells modified with high-affinity T-cell receptors (TCRs) to detect intracellular cancer antigens presented on MHC molecules.<\/p><\/li>

  • Tumor-Infiltrating Lymphocyte (TIL) Therapy<\/strong>
    Expansion of naturally occurring T cells extracted from tumors to enhance the body\u2019s intrinsic antitumor response.<\/p><\/li>

  • Personalized Cancer Vaccines<\/strong>
    mRNA- or peptide-based vaccines tailored to each patient\u2019s unique tumor mutations (neoantigens) to stimulate a targeted immune attack.<\/p><\/li>

  • Oncolytic Viruses<\/strong>
    Engineered viruses that selectively infect and destroy cancer cells while alerting the immune system to tumor presence.<\/p><\/li>

  • Innate Immune Modulation<\/strong>
    Therapies targeting natural killer (NK) cells, dendritic cells, and toll-like receptors (TLRs) to initiate and support adaptive immune responses.<\/p><\/li>

  • Engineered Cytokines<\/strong>
    Modified versions of immune-stimulating proteins like IL-2, IL-15, and IL-12 designed to boost immune activity with fewer side effects.<\/p><\/li>

  • Adenosine Pathway Inhibition<\/strong>
    Blocking immunosuppressive signaling (e.g., via CD73 or A2aR) within the tumor microenvironment to restore immune function.<\/p><\/li>

  • Antibody-Drug Conjugates (ADCs)<\/strong>
    Targeted delivery of cytotoxic agents directly to cancer cells via tumor-specific antibodies, reducing systemic toxicity.<\/p><\/li>

  • Neoantigen & Biomarker-Driven Therapies<\/strong>
    Leveraging genomic profiling and machine learning to identify optimal immunotherapy targets for personalized treatment.<\/p><\/li>

  • Immunotherapy Combinations<\/strong>
    Strategic use of immune agents alongside chemotherapy, radiation, targeted therapies, or other IO drugs to improve efficacy and durability.<\/p><\/li>

  • Off-the-Shelf Allogeneic Cell Therapies<\/strong>
    Scalable, donor-derived T or NK cell products using gene-editing technologies to enable immediate, broad patient access.<\/p><\/li>

  • Others<\/p><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

    Immuno-oncology is transforming cancer treatment by harnessing the power of the immune system to identify and eliminate tumors. Leading pharmaceutical and biotech companies are advancing a wide range of innovative approaches across the immuno-oncology landscape. Below are the key areas of focus shaping the future of cancer immunotherapy: Key Areas: Immune Checkpoint InhibitorsTargeting PD-1, PD-L1, […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-9890","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nImmuno-Oncology - Alliance for Immunology Innovations (AII)<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/eutranslationalmedicine.org\/aii\/immuno-oncology-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immuno-Oncology - Alliance for Immunology Innovations (AII)\" \/>\n<meta property=\"og:description\" content=\"Immuno-oncology is transforming cancer treatment by harnessing the power of the immune system to identify and eliminate tumors. Leading pharmaceutical and biotech companies are advancing a wide range of innovative approaches across the immuno-oncology landscape. Below are the key areas of focus shaping the future of cancer immunotherapy: Key Areas: Immune Checkpoint InhibitorsTargeting PD-1, PD-L1, […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/eutranslationalmedicine.org\/aii\/immuno-oncology-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Alliance for Immunology Innovations (AII)\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-06T17:07:42+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/immuno-oncology-2\\\/\",\"url\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/immuno-oncology-2\\\/\",\"name\":\"Immuno-Oncology - Alliance for Immunology Innovations (AII)\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/#website\"},\"datePublished\":\"2025-05-26T20:11:50+00:00\",\"dateModified\":\"2025-06-06T17:07:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/immuno-oncology-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/immuno-oncology-2\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/immuno-oncology-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immuno-Oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/#website\",\"url\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/\",\"name\":\"Alliance for Immunology Innovations (AII)\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/eutranslationalmedicine.org\\\/aii\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immuno-Oncology - Alliance for Immunology Innovations (AII)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/eutranslationalmedicine.org\/aii\/immuno-oncology-2\/","og_locale":"en_US","og_type":"article","og_title":"Immuno-Oncology - Alliance for Immunology Innovations (AII)","og_description":"Immuno-oncology is transforming cancer treatment by harnessing the power of the immune system to identify and eliminate tumors. Leading pharmaceutical and biotech companies are advancing a wide range of innovative approaches across the immuno-oncology landscape. Below are the key areas of focus shaping the future of cancer immunotherapy: Key Areas: Immune Checkpoint InhibitorsTargeting PD-1, PD-L1, […]","og_url":"https:\/\/eutranslationalmedicine.org\/aii\/immuno-oncology-2\/","og_site_name":"Alliance for Immunology Innovations (AII)","article_modified_time":"2025-06-06T17:07:42+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/eutranslationalmedicine.org\/aii\/immuno-oncology-2\/","url":"https:\/\/eutranslationalmedicine.org\/aii\/immuno-oncology-2\/","name":"Immuno-Oncology - Alliance for Immunology Innovations (AII)","isPartOf":{"@id":"https:\/\/eutranslationalmedicine.org\/aii\/#website"},"datePublished":"2025-05-26T20:11:50+00:00","dateModified":"2025-06-06T17:07:42+00:00","breadcrumb":{"@id":"https:\/\/eutranslationalmedicine.org\/aii\/immuno-oncology-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/eutranslationalmedicine.org\/aii\/immuno-oncology-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/eutranslationalmedicine.org\/aii\/immuno-oncology-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/eutranslationalmedicine.org\/aii\/"},{"@type":"ListItem","position":2,"name":"Immuno-Oncology"}]},{"@type":"WebSite","@id":"https:\/\/eutranslationalmedicine.org\/aii\/#website","url":"https:\/\/eutranslationalmedicine.org\/aii\/","name":"Alliance for Immunology Innovations (AII)","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/eutranslationalmedicine.org\/aii\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/pages\/9890","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/comments?post=9890"}],"version-history":[{"count":8,"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/pages\/9890\/revisions"}],"predecessor-version":[{"id":10049,"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/pages\/9890\/revisions\/10049"}],"wp:attachment":[{"href":"https:\/\/eutranslationalmedicine.org\/aii\/wp-json\/wp\/v2\/media?parent=9890"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}